Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $4.7 million.

  • Zevra Therapeutics' Cash from Operations rose 12595.78% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year increase of 6641.8%. This contributed to the annual value of -$69.7 million for FY2024, which is 10773.82% down from last year.
  • Per Zevra Therapeutics' latest filing, its Cash from Operations stood at $4.7 million for Q3 2025, which was up 12595.78% from -$3.6 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Cash from Operations high stood at $16.6 million for Q2 2021, and its period low was -$19.1 million during Q2 2024.
  • Moreover, its 5-year median value for Cash from Operations was -$4.5 million (2022), whereas its average is -$6.2 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 65709.07% in 2021, then tumbled by 42617.92% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Cash from Operations (Quarter) stood at -$848000.0 in 2021, then crashed by 426.18% to -$4.5 million in 2022, then plummeted by 262.12% to -$16.2 million in 2023, then dropped by 0.57% to -$16.2 million in 2024, then soared by 128.98% to $4.7 million in 2025.
  • Its Cash from Operations stands at $4.7 million for Q3 2025, versus -$3.6 million for Q2 2025 and -$8.2 million for Q1 2025.